Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quitoxil in Smoking Cessation
NCT07722832Not yet recruiting
- Sponsor
- KLAVA Innovation
- Start
- Oct 2026
- Primary completion
- Apr 2028
01
Overview
Randomised, open-label trial in Tobacco Use Disorder (TUD) (2 arms), sponsored by KLAVA Innovation. Primary endpoint: Clinical impact of using the Quitoxil device in the management of smoking cessation at 6 months. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT07722832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07722832.